Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 4:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Type 1 Diabetes
Interventions: AZD1656; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Heart Failure, Congestive
Interventions: GSK2798745 Micronized API without SLS and hypermellose (Tablet A), GSK2798745 Micronized API with SLS and hypermellose (Tablet B), GSK2798745 milled API without SLS and hypermellose (Tablet C); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Lacerations, Wounds
Interventions: Arm 2: Absorbable sutures, Arm 1: non-absorbable sutures; Other
Lead sponsor: Temple University; Other
Eligibility: 1 Year to 18 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: St Louis, Missouri • Philadelphia, Pennsylvania

Conditions: Dehydration, Menstruation, Pre-menopause, Peri-menopausal Women, Post-menopausal Women, Hydration
Interventions: placebo beverage, electrolyte beverage; Other
Lead sponsor: PepsiCo Global R&D; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Bradenton, Florida • Valhalla, New York

Conditions: Breast Cancer
Interventions: RealRisks; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 35 Years to 74 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: Lifestyle Factors, Customized use of Dietary Supplements, Currently Accepted Asthma Care Guidelines; Behavioral · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 19 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Insulin Resistance, Atherosclerosis, Cardiovascular Disease, HIV/AIDS, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 35 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy
Interventions: Oxycodone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Healthy
Interventions: Ondansetron Orally Disintegrating Tablets 8 mg, Zofran ODT® Tablets 8 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Type 2 Diabetes
Interventions: Intensification of diabetes medication based largely on HbA1c levels, Intensification of diabetes medication based on glucose levels; Other
Lead sponsor: Foundation for Atlanta Veterans Education and Research, Inc.; Other
Eligibility: 40 Years to 75 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Gastro Intestinal Bleeding, Hematemesis, Melena
Interventions: Video Capsule Endoscopy; Device
Lead sponsor: Christopher Marshall; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Infections, Bacterial
Interventions: Gepotidacin RC Tablet, Gepotidacin HSWG Tablet, Gepotidacin Capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Anaheim, California • Austin, Texas

Conditions: Prostate Cancer
Interventions: Enzalutamide Liquid, Enzalutamide Capsule; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Zidovudine tablets 300 mg; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2605541, Human Insulin NPH, Oral Antihyperglycemic Medications (OAM); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 20
States / cities: Tempe, Arizona • Concord, California • Fresno, California + 17 more

Conditions: Hypertension
Interventions: Irbesartan and Hydrochlorothiazide, Avalide; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Renal Impairment
Interventions: Lemborexant; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Type 1 Diabetes Mellitus
Interventions: SAR438544, placebo, r-glucagon; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Non-Hodgkins Lymphoma, Sarcoma, Neuroblastoma
Interventions: Food Safety Guidelines, Neutropenic Diet; Other
Lead sponsor: Indiana University; Other
Eligibility: 1 Year to 30 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 6
States / cities: San Diego, California • Indianapolis, Indiana • Brooklyn, New York + 2 more

Conditions: Obesity, Metabolic Disease, Cold Exposure
Interventions: Cold Vest Exposure Period, Rewarming Exposure Period, Fasting; Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Geriatric Disorder, Cancer, Patient Fall
Interventions: Stepping On Education Program, Home visit, Patient Questionnaire, Mini-Balance Evaluation Systems Test, GAITRite, Precise measure of movement testing; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 70 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy Participants
Interventions: Plixorafenib, Cobicistat; Drug
Lead sponsor: Fore Biotherapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Delayed Sleep Phase Syndrome
Interventions: Melatonin 0.5 MG, Dim Light Melatonin Onset (salivary); Drug · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy Male Subjects
Interventions: Savolitinib, Fluvoxamine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Search by objective public record fields.

To Evaluate the Bioavailability of a Tablet of AZD1656

A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets

Cosmetic Outcomes of Absorbable Versus Non-absorbable Sutures in Pediatric Facial Lacerations

Hydration & Female Life Stages

FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments

Functional Medicine in Asthma (FAst) Study

Human Atherosclerotic Plaque Inflammation Imaged Using PDG-PET/CT

Single-Dose, Crossover Study To Compare Bioavailability Of Two Formulations Under Fed And Fasted Conditions

Fasting Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mg

Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)

Study of Early Endocapsule (EC) in Clinical Decision Unit Versus Standard of Care Work-up for GI Bleeding

To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fasting Conditions

A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes

Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment

A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients

The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients

Thermogenic Silencer Regulatory Factors in Humans

Adaptation of the STEPPING ON Fall Prevention Program for Older Adults Receiving Cancer Therapy

A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.

The Clinical Utility of Measuring the Circadian Clock in Treatment of Delayed Sleep-Wake Phase Disorder

A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects